Ascorbic Acid Levels in MDS, AML, and CMML Patients

Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03526666

Enrollment

Registered

2018-05-16

Start date

2017-11-01

Completion date

2018-10-31

Last updated

2019-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia, AML, Chronic Myelomonocytic Leukemia, CMML, MDS, Myelodysplastic Syndromes

Keywords

Vitamin C, Ascorbic Acid, Epigenetics, 5-hydroxymethylcytosine, 5-methylcytosine

Brief summary

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

Detailed description

It has previously been established that hematological cancer patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency from a cohort of patients in Copenhagen. In this study, the investigators aim to determine if those results are conserved in another population/geographical location.

Interventions

OTHERPeripheral blood collection

Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients actively receiving treatment for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). * Patients diagnosed with AML, MDS, or CMML and are treatment naïve. * Patients who are 18 years old or older.

Exclusion criteria

* Patients deemed as too ill to participate as determined by the clinical investigator. * Non-English speaking patients * Patients unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Peripheral blood ascorbic acid levels	1 year	The level of ascorbic acid

Secondary

Measure	Time frame
Evaluation of human endogenous retroviral sequences (HERVs) expression	1 year
Evaluation of 5-methylcitosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) levels	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026